...
search icon
ipsc-img

Century Therapeutics Inc, Common Stock

IPSC

NSQ

$0.5

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$43.02M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
520.77K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.84
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.34 L
$3.7 H
$0.5

About Century Therapeutics Inc, Common Stock

Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial. In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameIPSCSectorS&P500
1-Week Return19.47%-1.78%-1%
1-Month Return-20.04%-7.14%-5.24%
3-Month Return-44.76%-3.43%-9.21%
6-Month Return-68.15%-11.08%-7.68%
1-Year Return-84.08%-1.72%6.77%
3-Year Return-95.48%-0.6%22.73%
5-Year Return-97.81%38.04%92.61%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-1.06M5.20M2.23M6.59M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":16.06,"profit":true},{"date":"2022-12-31","value":78.9,"profit":true},{"date":"2023-12-31","value":33.92,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue1.75M4.58M10.07M13.04M-[{"date":"2020-12-31","value":13.45,"profit":true},{"date":"2021-12-31","value":35.13,"profit":true},{"date":"2022-12-31","value":77.21,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit(1.75M)(4.58M)(4.87M)(10.81M)6.59M[{"date":"2020-12-31","value":-26.62,"profit":false},{"date":"2021-12-31","value":-69.54,"profit":false},{"date":"2022-12-31","value":-73.94,"profit":false},{"date":"2023-12-31","value":-164.05,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin-(433.08%)(93.71%)(483.62%)100.00%[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-433.08,"profit":false},{"date":"2022-12-31","value":-93.71,"profit":false},{"date":"2023-12-31","value":-483.62,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses49.18M94.88M139.03M148.78M144.73M[{"date":"2020-12-31","value":33.05,"profit":true},{"date":"2021-12-31","value":63.77,"profit":true},{"date":"2022-12-31","value":93.45,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":97.27,"profit":true}]
Operating Income(53.90M)(94.88M)(133.83M)(146.55M)(138.14M)[{"date":"2020-12-31","value":-5389800000,"profit":false},{"date":"2021-12-31","value":-9488300000,"profit":false},{"date":"2022-12-31","value":-13383100000,"profit":false},{"date":"2023-12-31","value":-14654600000,"profit":false},{"date":"2024-12-31","value":-13813700000,"profit":false}]
Total Non-Operating Income/Expense(58.00K)(2.17M)1.59M17.62M26.37M[{"date":"2020-12-31","value":-0.22,"profit":false},{"date":"2021-12-31","value":-8.24,"profit":false},{"date":"2022-12-31","value":6.01,"profit":true},{"date":"2023-12-31","value":66.84,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(53.58M)(95.78M)(130.84M)(134.79M)(124.78M)[{"date":"2020-12-31","value":-5357500000,"profit":false},{"date":"2021-12-31","value":-9578100000,"profit":false},{"date":"2022-12-31","value":-13084100000,"profit":false},{"date":"2023-12-31","value":-13479200000,"profit":false},{"date":"2024-12-31","value":-12477600000,"profit":false}]
Income Taxes1.08M43.00K91.00K1.88M1.79M[{"date":"2020-12-31","value":57.68,"profit":true},{"date":"2021-12-31","value":2.29,"profit":true},{"date":"2022-12-31","value":4.84,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":95.16,"profit":true}]
Income After Taxes(54.66M)(95.82M)(130.93M)(136.67M)(126.57M)[{"date":"2020-12-31","value":-5466000000,"profit":false},{"date":"2021-12-31","value":-9582400000,"profit":false},{"date":"2022-12-31","value":-13093200000,"profit":false},{"date":"2023-12-31","value":-13667300000,"profit":false},{"date":"2024-12-31","value":-12656600000,"profit":false}]
Income From Continuous Operations(53.58M)(95.82M)(130.93M)(128.96M)(126.57M)[{"date":"2020-12-31","value":-5357500000,"profit":false},{"date":"2021-12-31","value":-9582400000,"profit":false},{"date":"2022-12-31","value":-13093200000,"profit":false},{"date":"2023-12-31","value":-12895700000,"profit":false},{"date":"2024-12-31","value":-12656600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(54.66M)(95.82M)(130.93M)(136.67M)(126.57M)[{"date":"2020-12-31","value":-5466000000,"profit":false},{"date":"2021-12-31","value":-9582400000,"profit":false},{"date":"2022-12-31","value":-13093200000,"profit":false},{"date":"2023-12-31","value":-13667300000,"profit":false},{"date":"2024-12-31","value":-12656600000,"profit":false}]
EPS (Diluted)(0.95)(5.04)(4.00)(2.29)(1.55)[{"date":"2020-12-31","value":-95.17,"profit":false},{"date":"2021-12-31","value":-504,"profit":false},{"date":"2022-12-31","value":-400,"profit":false},{"date":"2023-12-31","value":-229,"profit":false},{"date":"2024-12-31","value":-155.42,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

IPSC
Cash Ratio 1.46
Current Ratio 1.50

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

IPSC
ROA (LTM) -23.67%
ROE (LTM) -73.14%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

IPSC
Debt Ratio Lower is generally better. Negative is bad. 0.54
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.46

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

IPSC
Trailing PE NM
Forward PE NM
P/S (TTM) 6.54
P/B 0.27
Price/FCF NM
EV/R 1.96
EV/Ebitda 0.08

FAQs

What is Century Therapeutics Inc share price today?

Century Therapeutics Inc (IPSC) share price today is $0.5

Can Indians buy Century Therapeutics Inc shares?

Yes, Indians can buy shares of Century Therapeutics Inc (IPSC) on Vested. To buy Century Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IPSC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Century Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Century Therapeutics Inc (IPSC) via the Vested app. You can start investing in Century Therapeutics Inc (IPSC) with a minimum investment of $1.

How to invest in Century Therapeutics Inc shares from India?

You can invest in shares of Century Therapeutics Inc (IPSC) via Vested in three simple steps:

  • Click on Sign Up or Invest in IPSC stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Century Therapeutics Inc shares
What is Century Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Century Therapeutics Inc (IPSC) is $3.7. The 52-week low price of Century Therapeutics Inc (IPSC) is $0.34.

What is Century Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Century Therapeutics Inc (IPSC) is 0.27

What is the Market Cap of Century Therapeutics Inc?

The market capitalization of Century Therapeutics Inc (IPSC) is $43.02M

What is Century Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Century Therapeutics Inc is IPSC

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top